ArticleCancer2015

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.

Diana P English et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.